Suppr超能文献

p63 是否可以作为骨巨细胞瘤的生物标志物?来自摩洛哥的经验。

Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience.

机构信息

Department of Pathology, HASSAN II University Hospital, Harazem, Fez, Morocco.

出版信息

Diagn Pathol. 2012 Sep 27;7:130. doi: 10.1186/1746-1596-7-130.

Abstract

BACKGROUND

Multinucleated giant cell-containing tumors and pseudotumors of bone represent a heterogeneous group of benign and malignant lesions. Differential diagnosis can be challenging, particularly in instances of limited sampling. The purpose of this study was to evaluate the contribution of the P63 in the positive and differential diagnosis of giant cell tumor of bone.

METHODS

This study includes 48 giant cell-containing tumors and pseudotumors of bone. P63 expression was evaluated by immunohistochemistry. Data analysis was performed using Epi-info software and SPSS software package (version 17).

RESULTS

Immunohistochemical analysis showed a P63 nuclear expression in all giant cell tumors of bone, in 50% of osteoid osteomas, 40% of aneurysmal bone cysts, 37.5% of osteoblastomas, 33.3% of chondromyxoide fibromas, 25% of non ossifiant fibromas and 8.3% of osteosarcomas. Only one case of chondroblastoma was included in this series and expressed p63. No P63 immunoreactivity was detected in any of the cases of central giant cell granulomas or langerhans cells histiocytosis. The sensitivity and negative predictive value (NPV) of P63 immunohistochemistry for the diagnosis of giant cell tumor of bone were 100%. The specificity and positive predictive value (PPV) were 74.42% and 59.26% respectively.

CONCLUSIONS

This study found not only that GCTOB expresses the P63 but it also shows that this protein may serve as a biomarker for the differential diagnosis between two morphologically similar lesions particularly in instances of limited sampling. Indeed, P63 expression seems to differentiate between giant cell tumor of bone and central giant cell granuloma since the latter does not express P63. Other benign and malignant giant cell-containing lesions express P63, decreasing its specificity as a diagnostic marker, but a strong staining was seen, except a case of chondroblastoma, only in giant cell tumor of bone. Clinical and radiological confrontation remains essential for an accurate diagnosis.

VIRTUAL SLIDES

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1838562590777252.

摘要

背景

多核巨细胞肿瘤和骨假瘤是一组具有异质性的良性和恶性病变。鉴别诊断具有挑战性,尤其是在有限采样的情况下。本研究旨在评估 P63 在骨巨细胞瘤的阳性和鉴别诊断中的作用。

方法

本研究包括 48 例骨多核巨细胞肿瘤和假瘤。通过免疫组织化学评估 P63 的表达。数据分析使用 Epi-info 软件和 SPSS 软件包(版本 17)进行。

结果

免疫组织化学分析显示,所有骨巨细胞瘤均有 P63 核表达,骨样骨瘤为 50%,动脉瘤样骨囊肿为 40%,成骨细胞瘤为 37.5%,软骨黏液样纤维瘤为 33.3%,非骨化性纤维瘤为 25%,骨肉瘤为 8.3%。本系列仅包括 1 例软骨母细胞瘤,表达 p63。中央性巨细胞肉芽肿或朗格汉斯细胞组织细胞增生症的任何病例均未检测到 P63 免疫反应性。P63 免疫组化诊断骨巨细胞瘤的敏感性和阴性预测值(NPV)均为 100%。特异性和阳性预测值(PPV)分别为 74.42%和 59.26%。

结论

本研究不仅发现 GCTOB 表达 P63,还表明该蛋白可能作为两种形态相似病变的鉴别诊断标志物,尤其是在有限采样的情况下。事实上,P63 的表达似乎可以区分骨巨细胞瘤和中央性巨细胞肉芽肿,因为后者不表达 P63。其他含有良性和恶性多核巨细胞的病变也表达 P63,降低了其作为诊断标志物的特异性,但除了 1 例软骨母细胞瘤外,在骨巨细胞瘤中均可见强烈染色。临床和影像学的对比对于准确诊断仍然至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31f6/3527302/afb650a1a5d7/1746-1596-7-130-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验